MAYNE PHARMA GROUP LIMITED — Director's Dealing 2008

Oct 14, 2008

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	HalcyGen Pharmaceuticals Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roger Aston
Date of last notice	3 July 2007

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Direct or indirect interest	Direct or indirect interest	Direct interest	Direct interest	Direct interest
	Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.		Direct interest (1)Newtonmore Biosciences Pty Ltd (2)
	Date of change		14 October 2008
	No. of secu	rities held prior to change	5,300,00	0 Ordinary Shares (1)	naryg 17naryg 17
			4,251,00625,000	0 Ordinary Shares (2) Unlisted options for ordi
				shares @ 60 cents expirinApril 2011 (1)
			625,000	Unlisted options for ordi
				shares @ 60 cents expirinApril 2012 (1)
	Class		Ordinary	fully paid shares
	Number ac	quired	3,303 (1	)
	Number di	sposed	Nil

• See chapter 19 for defined terms.

11/3/2002

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$835
No. of securities held after change	5,303,303 Ordinary Shares (1)4,251,000 Ordinary Shares (2)625,000Unlisted options for ordinaryshares @ 60 cents expiring 17April 2011 (1)625,000Unlisted options for ordinaryshares @ 60 cents expiring 17April 2012 (1)
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	On Market acquisition of ordinary shares

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002